193 related articles for article (PubMed ID: 23493335)
21. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.
Califano R; Landi L; Cappuzzo F
Drugs; 2012 Jun; 72 Suppl 1():28-36. PubMed ID: 22712795
[TBL] [Abstract][Full Text] [Related]
23. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
25. [Biomarkers in solid tumors].
Nagy Z
Magy Onkol; 2013 Mar; 57(1):56-62. PubMed ID: 23573523
[TBL] [Abstract][Full Text] [Related]
26. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
27. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
Kelley RK; Van Bebber SL; Phillips KA; Venook AP
J Natl Compr Canc Netw; 2011 Jan; 9(1):13-25. PubMed ID: 21233242
[TBL] [Abstract][Full Text] [Related]
28. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
[TBL] [Abstract][Full Text] [Related]
29. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
[TBL] [Abstract][Full Text] [Related]
30. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
[TBL] [Abstract][Full Text] [Related]
31. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
[TBL] [Abstract][Full Text] [Related]
32. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Taieb J; Jung A; Sartore-Bianchi A; Peeters M; Seligmann J; Zaanan A; Burdon P; Montagut C; Laurent-Puig P
Drugs; 2019 Sep; 79(13):1375-1394. PubMed ID: 31347092
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A; Ferrari P; Duffy MJ
Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
[TBL] [Abstract][Full Text] [Related]
35.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
36. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C; Umoru G
J Oncol Pharm Pract; 2024 Apr; ():10781552241242684. PubMed ID: 38576390
[TBL] [Abstract][Full Text] [Related]
37. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.
Afrăsânie VA; Marinca MV; Alexa-Stratulat T; Gafton B; Păduraru M; Adavidoaiei AM; Miron L; Rusu C
Radiol Oncol; 2019 Sep; 53(3):265-274. PubMed ID: 31553708
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
39. [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Belén Enguita A
Rev Esp Patol; 2023; 56(2):97-112. PubMed ID: 37061248
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
